Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Ars Pharmaceuticals Inc (SPRY)

Ars Pharmaceuticals Inc (SPRY)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
11.24 -0.54 (-4.58%) 02/21/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 11.21 -0.03 (-0.27%) 17:53 ET
Quote Overview for Fri, Feb 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
11.23
Day High
12.19
Open 12.15
Previous Close 11.78 11.78
Volume 1,390,700 1,390,700
Avg Vol 1,231,125 1,231,125
Stochastic %K 12.23% 12.23%
Weighted Alpha +13.21 +13.21
5-Day Change -0.68 (-5.70%) -0.68 (-5.70%)
52-Week Range 7.50 - 18.51 7.50 - 18.51
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,092,359
  • Shares Outstanding, K 97,185
  • Annual Sales, $ 30 K
  • Annual Income, $ -54,370 K
  • EBIT $ -61 M
  • EBITDA $ -67 M
  • 60-Month Beta 0.99
  • Price/Sales 422.90
  • Price/Cash Flow N/A
  • Price/Book 5.68

Options Overview Details

View History
  • Implied Volatility 82.23% ( -4.09%)
  • Historical Volatility 54.63%
  • IV Percentile 69%
  • IV Rank 63.23%
  • IV High 117.86% on 03/19/24
  • IV Low 20.97% on 06/10/24
  • Put/Call Vol Ratio 0.49
  • Today's Volume 719
  • Volume Avg (30-Day) 365
  • Put/Call OI Ratio 0.77
  • Today's Open Interest 16,973
  • Open Int (30-Day) 14,333

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.09
  • Number of Estimates 4
  • High Estimate 0.28
  • Low Estimate -0.29
  • Prior Year -0.07
  • Growth Rate Est. (year over year) -28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.23 +0.09%
on 02/21/25
Period Open: 13.48
15.19 -26.00%
on 01/27/25
-2.24 (-16.62%)
since 01/21/25
3-Month
10.20 +10.20%
on 12/27/24
Period Open: 13.38
15.19 -26.00%
on 01/27/25
-2.14 (-15.99%)
since 11/21/24
52-Week
7.50 +49.87%
on 02/22/24
Period Open: 7.46
18.51 -39.28%
on 11/11/24
+3.78 (+50.67%)
since 02/21/24

Most Recent Stories

More News
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients

SPRY : 11.24 (-4.58%)
ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

SPRY : 11.24 (-4.58%)
ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference

SPRY : 11.24 (-4.58%)
ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools

SPRY : 11.24 (-4.58%)
ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)

SPRY : 11.24 (-4.58%)
ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

SPRY : 11.24 (-4.58%)
ARS Pharmaceuticals’ neffy® Added to Express Scripts Commercial National Formularies, Enhancing Access for Allergy Patients

Neffy nasal spray included in Express Scripts formularies enhances access for patients with Type 1 allergic reactions.Quiver AI SummaryARS Pharmaceuticals, Inc. announced that neffy® (epinephrine nasal...

SPRY : 11.24 (-4.58%)
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

SPRY : 11.24 (-4.58%)
ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

SPRY : 11.24 (-4.58%)
Insider Sale: Chief Business Officer of $SPRY (SPRY) Sells 27,272 Shares

Justin Chakma, the Chief Business Officer of $SPRY ($SPRY), sold 27,272 shares of the company on 12-13-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 16.7%...

SPRY : 11.24 (-4.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

ARS Pharmaceuticals Inc. is dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions which could lead to anaphylaxis. The company is developing neffy(TM) an intranasal epinephrine product in clinical development for patients and their caregivers...

See More

Key Turning Points

3rd Resistance Point 12.83
2nd Resistance Point 12.51
1st Resistance Point 11.88
Last Price 11.24
1st Support Level 10.92
2nd Support Level 10.59
3rd Support Level 9.96

See More

52-Week High 18.51
Fibonacci 61.8% 14.30
Fibonacci 50% 13.01
Fibonacci 38.2% 11.71
Last Price 11.24
52-Week Low 7.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements